As a leading team in this area, we have in depth knowledge of the regulatory system for stock market transactions, and can add value in both strategic and structural matters.
The team is heavily involved in developing the regulations in this area, and we have well established contacts with authorities and other participants on the Swedish stock market.
Through our international network, we regularly handle transactions that span two or more jurisdictions.
The team has specialist competence in Equity Capital Market transactions (such as listings, capital raising and sell downs), as well as public M&A.
Vinge also has extensive experience advising on: disclosure matters (rules on disclosure of information, market abuse and disclosure of shareholding and short selling); corporate governance (preparing for general meetings, questions about board composition and reporting); and incentive programmes for listed companies.
Because no two transactions are the same, we put together a unique team for each project – one that is built around the client’s needs.
Clients will find they work with a team that has detailed knowledge of business law and is readily available to them. Because we are a full‑service firm, we can support our clients in all their business law matters.
Sources highlight the lawyers' impressive track record in the capital markets arena: "They obviously have huge experience of listings in Sweden and the Nordics - there are always obstacles and unexpected things that happen, but they have done it so many times and are well connected so they can solve all of these." Clients appreciate the team's high level of customer care: "They were very easy to contact, service-minded and very patient in their explanations. They made us feel at ease and we got the support we needed, when we needed it." (Chambers and Partners 2019)
The team is 'extremely dedicated, always has a commercial approach' (Legal 500 2019)
Vinge advises Xspray Pharma AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm. The prospectus was published on 23 March 2020 and the trading on Nasdaq Stockholm commenced on 27 March 2020.
Vinge has advised the pharmaceutical development company Cinclus Pharma in connection with a capital raising of approximately SEK 250 million by way of a directed share issue to several new investors and current shareholders.
Cantargia AB (publ) makes a directed share issue of approximately SEK 410 million to a number of Swedish and international investors.